Skip to content

Debt-to-assets at other companies

Pfizer logo
PfizerPFE
0.3×0.0×
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
0.1×0.0×
PTC Therapeutics logo
PTC TherapeuticsPTCT
0.1×0.0×
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
0.0×
Vericel logo
VericelVCEL
0.2×0.0×
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
0.2×+0.1×

Other financials

Income statement

See full
Revenue--100%
Operating income-$36.8M-47.2%
Net income-$33.9M-39.2%
EPS (diluted)-$0.59-11.3%

Balance sheet

See full
Cash & equivalents$105.4M+266%
Total debt$14.8M+1,083%
Total equity$278.7M+118%
Total assets$326.3M+112%

Cash flow

See full
Operating cash flow-$29.3M-355%
CapEx$5.1M+472%
Free cash flow-$34.4M-369%

Valuation

See full
Market cap$1.71B+303%

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-56.4%-11.3pp
Debt / equity0.1×0.0×
Current ratio8.4×+1.9×

Where this comes from

Calculated from Capricor Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Capricor Therapeutics's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Capricor Therapeutics's debt-to-assets?
Capricor Therapeutics (CAPR) reported debt-to-assets of 0× in Q1 2026.
How has Capricor Therapeutics's debt-to-assets changed year-over-year?
Capricor Therapeutics's debt-to-assets increased by 459.3% year-over-year, from 0× to 0×.
What is the long-term trend for Capricor Therapeutics's debt-to-assets?
Over 5 years (2020 to 2025), Capricor Therapeutics's debt-to-assets has grown at a 81.0% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.